Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company.
It operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse.
In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -2.33 Increased by +76.09% | - |
| Nov 12, 24 | -4.17 Decreased by -113.83% | -3.90 Decreased by -6.92% |
| Aug 14, 24 | -5.20 Increased by +42.83% | -3.90 Decreased by -33.33% |
| May 14, 24 | -3.25 Increased by +80.44% | -3.25 |
| Mar 29, 24 | -9.75 Increased by +19.61% | -9.10 Decreased by -7.14% |
| Nov 15, 23 | -1.95 Increased by +73.91% | -9.10 Increased by +78.57% |
| Aug 11, 23 | -9.10 Increased by +5.22% | - |
| May 18, 23 | -16.61 Decreased by -60.18% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -5.36 M Decreased by -305.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.83 M Decreased by -261.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -3.11 M Increased by +43.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.90 M Decreased by N/A% | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -1.32 M - | Decreased by N/A% - |
| Sep 30, 23 | 0.00 - | -1.06 M - | Decreased by N/A% - |
| Jun 30, 23 | 0.00 - | -5.49 M - | Decreased by N/A% - |
| Mar 31, 23 | N/A - | N/A - | - - |